Status:
COMPLETED
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Collaborating Sponsors:
Astellas Pharma Inc
Conditions:
Involutional Osteoporosis
Eligibility:
FEMALE
55-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.
Eligibility Criteria
Inclusion
- Patients who was included in study ONO-5920-02 and completed the medication for two years
- Other inclusion criteria as specified in the study protocol
Exclusion
- Patients judged to be unsuitable by safety evaluation as clinical trial subjects by the investigator
- Patients having secondary osteoporosis or another condition that presents low bone mass
- Other exclusion criteria as specified in the study protocol
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
444 Patients enrolled
Trial Details
Trial ID
NCT00212628
Start Date
June 1 2004
Last Update
June 14 2012
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Chugoku Region Facility
Chugoku, Japan
2
Chubu Region Facility
Chūbu, Japan
3
Hokkaido Region Facility
Hokkaido, Japan
4
Hokuriku Region Facility
Hokuriku, Japan